SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15

Journal of Cellular Physiology

Volumn 204, Issue 3, 2005, Pages 785-791

  Hung, Huynh ^a   Pierce, Chow Kad Hoe ^b   Chee, Soo Khee ^a   Lawrence, Panasci ^c   Hung, Nguyen Thanh ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROETHYL 3 SARCOSINAMIDE 1 NITROSOUREA; CYCLIN DEPENDENT KINASE 1; NITROSOUREA DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG; 2 ((((2 CHLOROETHYL)NITROSOAMINO)CARBONYL)AMINO)PROPANAMIDE; 2-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)AMINO)PROPANAMIDE; CARMUSTINE; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE; PHOSPHOTYROSINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ASSAY; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CELL CYCLE G2 PHASE; CELL PROLIFERATION; DRUG EFFECT; GENETICS; LIVER TUMOR; METABOLISM; MITOSIS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CARMUSTINE; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; HUMANS; LIVER NEOPLASMS; MITOSIS; PHOSPHORYLATION; PHOSPHOTYROSINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23344431971     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20336     Document Type: Article

References (41)

1. Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringe B, Meyers WC. 1998. Hepatocellular carcinoma. Br J Surg 85:1319-1331.
2. Casagrande F, Darbon JM. 2001. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: Regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 61:1205-1215.
3. Castedo M, Perfettini JL, Roumier T, Kroemer G. 2002. Cyclin-dependent kinase-1: Linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9:1287-1293.
4. Chan TA, Hermeking H, Lengauer C, Kanzler KW, Vogelstein B. 1999. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620.
5. Chan ES, Chow PK, Tai B, Machin D, Soo K. 2000. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev CD001199.
6. Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. 1999. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med 123:524-528.
7. Chen ZP, Remack J, Brent TP, Mohr G, Panasci LC. 1999a. Extraneuronal monoamine transporter expression and DNA repair vis-a-vis 2-chloroethyl-3- sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines. Clin Cancer Res 5:4186-4190.
8. Chen ZP, Wang G, Huang Q, Sun ZF, Zhou LY, Wang AD, Panasci LC. 1999b. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neurooncol 44:7-14.
9. Chen ZP, Pan J, Huang Q, Sun ZF, Zhou LY, Wang AD. 2001. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. J Neurooncol 51:19-24.
10. Colombo M. 1992. Hepatocellular carcinoma. J Hepatol 15:225-236.
11. Dalal SN, Schweitzer CM, Gan J, DeCaprio JA. 1999. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 19:4465-4479.
12. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. 2000. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 20:4210-4223.
13. 2/M progression. Mol Cell 1:3-11.
14. Huguet CSFaGA. 2000. Primary hepatocellular cancer: Western experience. In: Blumgart L, editor. Surgery of the liver and biliary tract. London: Churchill Livingstone. pp 1365-1369.
15. Hui AM, Makuuchi M, Li X. 1998. Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 45:1635-1642.
16. Huynh H, Chow PK, Ooi LL, Soo KC. 2002. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13:115-122.
17. Ince N, Wands JE. 1999. The increasing incidence of hepatocellular carcinoma. N Engl J Med 340:798-799.
18. 2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 96:2147-2152.
19. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M. 1999. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30:90-99.
20. 2/M transition. Oncogene 21:1717-1726.
21. Konishi Y, Lehtinen M, Donovan N, Bonni A. 2002. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 9:1005-1016.
22. Lai EaWJ. 1994. Hepatocellular carcinoma: The Asian experience. In: Blumgart L, editor. Surgery of the liver and the biliary tract. London: Churchill Livingstone. pp 1349-1363.
23. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. 1995. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221:291-298.
24. Marcantonio D, Panasci LC, Hollingshead MG, Alley MC, Camalier RF, Sausville EA, Dykes DJ, Carter CA, Malspeis L. 1997. 2-Chloroethyl-3- sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res 57:3895-3898.
25. Mitry RR, Sarraf CE, Havlik R, Habib NA. 2000. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology 31:885-889.
26. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. 1991. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51:5520-5525.
27. Nigg EA. 2001. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21-32.
28. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. 1985. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918-928.
29. Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Jr. Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E. 2003. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: A phase I and pharmacokinetic study in patients with advanced solid tumors. J Clin Oncol 21:232-240.
30. Peng SY, Chou SP, Hsu HC. 1998. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol 29:281-289.
31. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, Ozturk M. 1993. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7:1407-1413.
32. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A, Coggi G. 2002. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 36:427-432.
33. Schafer DF, Sorrell MF. 1999. Hepatocellular carcinoma. Lancet 353:1253-1257.
34. Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W. 1988. The cytotoxicity of sarcosinamide chioroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: Analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 22:137-140.
35. Skalski V, Feindel W, Panasci LC. 1989. The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport. J Neurooncol 7:189-193.
36. Smits VA, Medema RH. 2001. Checking out the G(2)/M transition. Biochim Biophys Acta 1519:1-12.
37. 2 DNA damage checkpoint. J Biol Chem 275:30638-30643.
38. Takenaka K, Kawahara N, Yamamoto K, Kajiyama K, Maeda T, Itasaka H, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. 1996. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 131:71-76.
39. Tang Z, Coleman TR, Dunphy WG. 1993. Two distinct mechanisms for negative regulation of the Weel protein kinase. EMBO J 12:3427-3436.
40. Taylor WR, Schonthal AH, Galante J, Stark GR. 2001. p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem 276:1998-2006.
41. Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC. 2002. Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene 21:4932-4943.